An important limitation of current knowledge regarding the role of B cells in autoimmunity is that very little is known in human disease beyond the production of autoantibodies. Yet, accumulating data in diverse autoimmune diseases, including Systemic Lupus Erythematosus (SLE), indicates that B cells likely contribute to disease through multiple mechanisms that include both antibody-dependent and antibody-independent functions. The latter include antigenpresentation, T-cell activation and polarization, and dendritic cell modulation and we propose are critically mediated by the ability of B cells to produce cytokines. B cells may be deleterious through the production of pro-inflammatory cytokines and pathogenic autoantibodies or regulatory through the production of anti-inflammatory cytokines such as IL- 10 and TGFp and the expansion of Tregs and/or inhibition of effector T cells. Understanding the imbalance between these opposing B cell functions in disease is the overarching concept of this project and overall ACE proposal. It is founded on substantial preliminary evidence indicating that human B cells display phenotypic diversity that reflects division of labor for effector and regulatory functions, their sriking imbalance in SLE, and their reversal in patients experiencing good clinical response after B cell depletion and reconstitution. This imbalance could result from either: 1) numerical advantage in one population;or 2) a gain-of-pathogenic function and/or loss-of-regulatory function within a given population. Our preliminary view of a profile characteristic of active SLE includes the expansion of presumed effector subsets (switched CD27+ and CD27- cells) and/or the deficit of populations with regulatory potential (transitional, naTve and MZ cells). These assumptions will be addressed in Aim 1. We recognize however that surface phenotype is insufficient to determine the function of any given subset and therefore, Aim 2 will test the function of separate subsets in terms of cytokine producing potential and ability to modulate T cell function. Finally, we surmise that the fluctuating B cell imbalances that create a distinctive B cell signature in SLE PBL reflect recurrent systemic autoimmune responses dominated by antigen specificities known to fluctuate with disease activity. This contention represents the basis for Aim 3 which will test the contribution of specific autoreactivity to the expansion of effector and regulatory B cell subsets. Overall, we predict that effector B cells will be characterized by an activated phenotype and enhanced replication, potential for migration to non-lymphoid systemic tissues and production of pro-inflammatory cytokines. In contrast, regulatory B cells will display limited replication and specialize in the production of antiinflammatory cytokines. The information derived from these aims will be critical to understand whether a gain-ofpathogenic function and/or loss of protective B cell function help explain why clinical disease typically ensues years after the initial breakdown of tolerance, what type of B cell imbalance (either in number or function) underlies disease onset, exacerbation and remission and how to manipulate this knowledge for diagnostic, prognostic and therapeutic advantage.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI056390-10
Application #
8468979
Study Section
Special Emphasis Panel (ZAI1-QV-I)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
10
Fiscal Year
2013
Total Cost
$254,081
Indirect Cost
$58,260
Name
University of Rochester
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Segal, Benjamin M (2014) Stage-specific immune dysregulation in multiple sclerosis. J Interferon Cytokine Res 34:633-40
Palanichamy, Arumugam; Bauer, Jason W; Yalavarthi, Srilakshmi et al. (2014) Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. J Immunol 192:906-18
Zhang, Hengwei; Hilton, Matthew J; Anolik, Jennifer H et al. (2014) NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-?B. J Clin Invest 124:3200-14
Roberts, Mustimbo E P; Kaminski, Denise; Jenks, Scott A et al. (2014) Primary Sjögren's syndrome is characterized by distinct phenotypic and transcriptional profiles of IgD+ unswitched memory B cells. Arthritis Rheumatol 66:2558-69
Jones, Meghan C; Kobie, James J; Delouise, Lisa A (2013) Characterization of cell seeding and specific capture of B cells in microbubble well arrays. Biomed Microdevices 15:453-63
Feng, Changyong; Wang, Hongyue; Lu, Naiji et al. (2013) Log transformation: application and interpretation in biomedical research. Stat Med 32:230-9
Richardson, Christopher; Chida, Asiya Seema; Adlowitz, Diana et al. (2013) Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus. J Immunol 191:4926-39
Oleksyn, David; Pulvino, Mary; Zhao, Jiyong et al. (2013) Protein kinase Cýý is required for lupus development in Sle mice. Arthritis Rheum 65:1022-31
Huang, Yu-Hui; Sojka, Dorothy K; Fowell, Deborah J (2012) Cutting edge: Regulatory T cells selectively attenuate, not terminate, T cell signaling by disrupting NF-ýýB nuclear accumulation in CD4 T cells. J Immunol 188:947-51
Ching, Kathryn H; Burbelo, Peter D; Tipton, Christopher et al. (2012) Two major autoantibody clusters in systemic lupus erythematosus. PLoS One 7:e32001

Showing the most recent 10 out of 55 publications